AP2184A - Benzimidazolone compounds having 5-HT4 receptor agonistic activity. - Google Patents
Benzimidazolone compounds having 5-HT4 receptor agonistic activity.Info
- Publication number
- AP2184A AP2184A AP2006003536A AP2006003536A AP2184A AP 2184 A AP2184 A AP 2184A AP 2006003536 A AP2006003536 A AP 2006003536A AP 2006003536 A AP2006003536 A AP 2006003536A AP 2184 A AP2184 A AP 2184A
- Authority
- AP
- ARIPO
- Prior art keywords
- agonistic activity
- receptor agonistic
- benzimidazolone compounds
- benzimidazolone
- compounds
- Prior art date
Links
- 108091005482 5-HT4 receptors Proteins 0.000 title 1
- 230000001270 agonistic effect Effects 0.000 title 1
- 150000008641 benzimidazolones Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Manufacturing & Machinery (AREA)
- Cardiology (AREA)
- Ceramic Engineering (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50014403P | 2003-09-03 | 2003-09-03 | |
| PCT/IB2004/002741 WO2005021539A1 (en) | 2003-09-03 | 2004-08-20 | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2006003536A0 AP2006003536A0 (en) | 2006-04-30 |
| AP2184A true AP2184A (en) | 2010-12-02 |
Family
ID=34272920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2006003536A AP2184A (en) | 2003-09-03 | 2004-08-20 | Benzimidazolone compounds having 5-HT4 receptor agonistic activity. |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US7776885B2 (da) |
| EP (1) | EP1664036B1 (da) |
| JP (1) | JP3983269B1 (da) |
| KR (1) | KR100738784B1 (da) |
| CN (1) | CN100482659C (da) |
| AP (1) | AP2184A (da) |
| AR (1) | AR045552A1 (da) |
| AT (1) | ATE539077T1 (da) |
| AU (1) | AU2004268840B9 (da) |
| BR (1) | BRPI0414105B8 (da) |
| CA (1) | CA2537127C (da) |
| CR (1) | CR8267A (da) |
| CY (1) | CY1112321T1 (da) |
| DK (1) | DK1664036T3 (da) |
| EA (1) | EA009457B1 (da) |
| EC (1) | ECSP066407A (da) |
| ES (1) | ES2377484T3 (da) |
| GE (1) | GEP20084527B (da) |
| GT (1) | GT200400174A (da) |
| HK (1) | HK1093338A1 (da) |
| HR (1) | HRP20120077T1 (da) |
| IL (3) | IL173705A (da) |
| IS (1) | IS8289A (da) |
| MA (1) | MA28021A1 (da) |
| MX (1) | MXPA06002550A (da) |
| NL (1) | NL1026959C2 (da) |
| NO (1) | NO20061519L (da) |
| OA (1) | OA13248A (da) |
| PA (1) | PA8610601A1 (da) |
| PE (1) | PE20050874A1 (da) |
| PL (1) | PL1664036T3 (da) |
| PT (1) | PT1664036E (da) |
| RS (1) | RS20060145A (da) |
| SI (1) | SI1664036T1 (da) |
| TN (1) | TNSN06073A1 (da) |
| TW (1) | TW200510332A (da) |
| UA (1) | UA86204C2 (da) |
| UY (1) | UY28496A1 (da) |
| WO (1) | WO2005021539A1 (da) |
| ZA (1) | ZA200601324B (da) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物 |
| GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
| SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| GEP20084527B (en) * | 2003-09-03 | 2008-11-10 | Pfizer | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
| TW200533348A (en) | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7728006B2 (en) | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| MXPA06014486A (es) * | 2004-06-15 | 2007-03-01 | Pfizer | Derivados de acido carboxilico de bencimidazolona. |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| EP1807422B1 (en) | 2004-11-05 | 2009-09-02 | Theravance, Inc. | 5-ht4 receptor agonist compounds |
| US7396933B2 (en) | 2004-11-05 | 2008-07-08 | Theravance, Inc. | Quinolinone-carboxamide compounds |
| ATE469897T1 (de) | 2004-12-22 | 2010-06-15 | Theravance Inc | Indazolcarbonsäureamidverbindungen |
| EP1856110B1 (en) | 2005-02-22 | 2011-06-22 | Pfizer Inc. | Oxyindole derivatives as 5ht4 receptor agonists |
| BRPI0608392A2 (pt) | 2005-03-02 | 2009-12-29 | Theravance Inc | compostos de quinolinona como agonistas do receptor 5-ht4 |
| EP1861377B1 (en) * | 2005-03-15 | 2010-12-29 | Pfizer, Inc. | Benzimidazolone derivatives as cb2 receptor ligands |
| MY147756A (en) | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
| JP5086248B2 (ja) * | 2005-06-07 | 2012-11-28 | セラヴァンス， インコーポレーテッド | ５−ｈｔ４受容体アゴニストとしてのベンゾイミダゾロン−カルボキサミド化合物 |
| ES2391107T3 (es) | 2005-09-30 | 2012-11-21 | Glaxo Group Limited | Compuestos que tienen actividad en el receptor M1 y sus usos en medicina |
| JP5209479B2 (ja) * | 2005-09-30 | 2013-06-12 | グラクソ グループ リミテッド | Ｍ１受容体にて活性を有するベンゾイミダゾロン類 |
| US8283364B2 (en) * | 2005-09-30 | 2012-10-09 | Glaxo Group Limited | Compounds which have activity at M1 receptor and their uses in medicine |
| CA2625210A1 (en) * | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| MY143574A (en) * | 2005-11-22 | 2011-05-31 | Theravance Inc | Carbamate compounds as 5-ht4 receptor agonists |
| GB0525068D0 (en) | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| UY30048A1 (es) | 2005-12-23 | 2007-07-31 | Astrazeneca Ab | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
| EP1984027B1 (en) * | 2006-01-24 | 2015-12-30 | R-Tech Ueno, Ltd. | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
| TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
| US20080318964A1 (en) * | 2007-06-19 | 2008-12-25 | Protia, Llc | Deuterium-enriched eszopiclone |
| GB0718415D0 (en) * | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
| US8642772B2 (en) | 2008-10-14 | 2014-02-04 | Sk Biopharmaceuticals Co., Ltd. | Piperidine compounds, pharmaceutical composition comprising the same and its use |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| US8232315B2 (en) | 2009-06-26 | 2012-07-31 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating drug addiction and improving addiction-related behavior |
| JP5836280B2 (ja) | 2009-11-06 | 2015-12-24 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 注意欠陥／多動性障害（ａｄｈｄ）の治療方法 |
| JP5901528B2 (ja) | 2009-11-06 | 2016-04-13 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 線維筋痛症候群の治療方法 |
| WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
| AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| MX343165B (es) * | 2010-02-12 | 2016-10-26 | Raqualia Pharma Inc | Agonistas del receptor 5-ht4 para el tratamiento de demencia. |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| WO2012074721A2 (en) * | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Delivery of serotonin receptor antagonists by microinjection systems |
| US8546416B2 (en) | 2011-05-27 | 2013-10-01 | Novartis Ag | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
| AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| WO2017093890A1 (en) * | 2015-11-30 | 2017-06-08 | Piramal Enterprises Limited | Clobazam tablet formulation and process for its preparation |
| KR20220054211A (ko) * | 2020-10-23 | 2022-05-02 | 에이치케이이노엔 주식회사 | 벤즈이미다졸 유도체 화합물을 포함하는 구강붕해정 및 이의 제조방법 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0522914A1 (fr) * | 1991-06-27 | 1993-01-13 | Synthelabo | Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique |
| WO2000037461A1 (en) * | 1998-12-22 | 2000-06-29 | Janssen Pharmaceutica N.V. | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| WO2002053568A1 (fr) * | 2000-12-28 | 2002-07-11 | Mochida Pharmaceutical Co., Ltd. | Inhibiteurs de la biosynthese du cholesterol contenant comme principe actif des composes spiro tricycliques |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US63716A (en) * | 1867-04-09 | Improved cheery stoner | ||
| CH566987A5 (da) * | 1972-04-21 | 1975-09-30 | Ciba Geigy Ag | |
| US3945953A (en) * | 1972-04-21 | 1976-03-23 | Ciba-Geigy Corporation | ω,ω'-Bis-[4-amino-3-aminomethyl-piperidyl-(1)]-alkanes, process for their manufacture and their use |
| DE3336024A1 (de) * | 1983-10-04 | 1985-04-18 | Boehringer Ingelheim KG, 6507 Ingelheim | 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel |
| US5223511A (en) | 1987-09-23 | 1993-06-29 | Boehringer Ingelheim Italia S.P.A. | Benzimidazoline-2-oxo-1-carboxylic acid compounds useful as 5-HT receptor antagonists |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| IT1251144B (it) * | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
| GB9204565D0 (en) * | 1992-03-03 | 1992-04-15 | Smithkline Beecham Plc | Pharmaceuticals |
| US5300512A (en) | 1992-06-24 | 1994-04-05 | G. D. Searle & Co. | Benzimidazole compounds |
| AU680453B2 (en) | 1992-11-05 | 1997-07-31 | Smithkline Beecham Plc | Piperidine derivatives as 5-HT4 receptor antagonists |
| TW252206B (da) * | 1993-09-01 | 1995-07-21 | Philips Electronics Nv | |
| IT1275903B1 (it) * | 1995-03-14 | 1997-10-24 | Boehringer Ingelheim Italia | Esteri e ammidi della 1,4-piperidina disostituita |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| AU9309898A (en) | 1997-09-09 | 1999-03-29 | Du Pont Pharmaceuticals Company | Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa |
| US6069152A (en) * | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
| US6420410B1 (en) | 1998-11-24 | 2002-07-16 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones |
| SE0301446D0 (sv) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
| GEP20084527B (en) * | 2003-09-03 | 2008-11-10 | Pfizer | Benzimidazolone compounds having 5-ht4 receptor agonistic activity |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| MXPA06014486A (es) | 2004-06-15 | 2007-03-01 | Pfizer | Derivados de acido carboxilico de bencimidazolona. |
| MY147756A (en) * | 2005-05-25 | 2013-01-15 | Theravance Inc | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists |
-
2004
- 2004-08-20 GE GEAP20049270A patent/GEP20084527B/en unknown
- 2004-08-20 BR BRPI0414105A patent/BRPI0414105B8/pt not_active IP Right Cessation
- 2004-08-20 DK DK04744319.7T patent/DK1664036T3/da active
- 2004-08-20 EP EP04744319A patent/EP1664036B1/en active Active
- 2004-08-20 OA OA1200600069A patent/OA13248A/en unknown
- 2004-08-20 AP AP2006003536A patent/AP2184A/xx active
- 2004-08-20 EA EA200600327A patent/EA009457B1/ru not_active IP Right Cessation
- 2004-08-20 SI SI200431820T patent/SI1664036T1/sl unknown
- 2004-08-20 CA CA2537127A patent/CA2537127C/en active Active
- 2004-08-20 AT AT04744319T patent/ATE539077T1/de active
- 2004-08-20 PT PT04744319T patent/PT1664036E/pt unknown
- 2004-08-20 UA UAA200602293A patent/UA86204C2/uk unknown
- 2004-08-20 PL PL04744319T patent/PL1664036T3/pl unknown
- 2004-08-20 RS YUP-2006/0145A patent/RS20060145A/sr unknown
- 2004-08-20 AU AU2004268840A patent/AU2004268840B9/en not_active Ceased
- 2004-08-20 CN CNB2004800252755A patent/CN100482659C/zh not_active Expired - Fee Related
- 2004-08-20 MX MXPA06002550A patent/MXPA06002550A/es active IP Right Grant
- 2004-08-20 KR KR1020067004335A patent/KR100738784B1/ko active IP Right Grant
- 2004-08-20 WO PCT/IB2004/002741 patent/WO2005021539A1/en active Application Filing
- 2004-08-20 JP JP2006525197A patent/JP3983269B1/ja active Active
- 2004-08-20 ES ES04744319T patent/ES2377484T3/es active Active
- 2004-08-31 PE PE2004000831A patent/PE20050874A1/es not_active Application Discontinuation
- 2004-09-01 AR ARP040103133A patent/AR045552A1/es not_active Application Discontinuation
- 2004-09-02 UY UY28496A patent/UY28496A1/es not_active Application Discontinuation
- 2004-09-02 PA PA20048610601A patent/PA8610601A1/es unknown
- 2004-09-02 GT GT200400174A patent/GT200400174A/es unknown
- 2004-09-02 US US10/933,629 patent/US7776885B2/en active Active
- 2004-09-02 TW TW093126507A patent/TW200510332A/zh unknown
- 2004-09-03 NL NL1026959A patent/NL1026959C2/nl not_active IP Right Cessation
-
2006
- 2006-02-09 IS IS8289A patent/IS8289A/is unknown
- 2006-02-13 IL IL173705A patent/IL173705A/en not_active IP Right Cessation
- 2006-02-14 ZA ZA200601324A patent/ZA200601324B/en unknown
- 2006-03-02 CR CR8267A patent/CR8267A/es not_active Application Discontinuation
- 2006-03-03 EC EC2006006407A patent/ECSP066407A/es unknown
- 2006-03-03 MA MA28851A patent/MA28021A1/fr unknown
- 2006-03-03 TN TNP2006000073A patent/TNSN06073A1/en unknown
- 2006-04-03 NO NO20061519A patent/NO20061519L/no not_active Application Discontinuation
- 2006-12-21 HK HK06114049.6A patent/HK1093338A1/xx not_active IP Right Cessation
-
2010
- 2010-05-06 IL IL205600A patent/IL205600A0/en unknown
- 2010-05-06 IL IL205599A patent/IL205599A0/en unknown
- 2010-07-07 US US12/831,713 patent/US20100273794A1/en not_active Abandoned
-
2012
- 2012-01-23 HR HR20120077T patent/HRP20120077T1/hr unknown
- 2012-02-06 CY CY20121100124T patent/CY1112321T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0522914A1 (fr) * | 1991-06-27 | 1993-01-13 | Synthelabo | Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique |
| WO2000037461A1 (en) * | 1998-12-22 | 2000-06-29 | Janssen Pharmaceutica N.V. | 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| WO2002053568A1 (fr) * | 2000-12-28 | 2002-07-11 | Mochida Pharmaceutical Co., Ltd. | Inhibiteurs de la biosynthese du cholesterol contenant comme principe actif des composes spiro tricycliques |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2184A (en) | Benzimidazolone compounds having 5-HT4 receptor agonistic activity. | |
| IL160945A0 (en) | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity | |
| IL178086A0 (en) | Quinolinone-carboxamide compounds as 5-ht4 receptor agonists | |
| AU2002353403A8 (en) | Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators | |
| IL174990A0 (en) | Compounds having crth2 antagonist activity | |
| EP1559422A4 (en) | CONTROLLER OF RECEIVER FUNCTION | |
| PL1687390T3 (pl) | Zgazowanie katalityczne | |
| EP1648867A4 (en) | PPAR-ACTIVE COMPOUNDS | |
| GB0325093D0 (en) | Fiberglass nonwoven catalyst | |
| MA27306A1 (fr) | Ligands des recepteurs de la melanocortine. | |
| EP1631559A4 (en) | IL-8 SB / SB RECEPTOR ANTAGONISTS | |
| IS2897B (is) | Efnasambönd sem hamla gegn virkni kalkviðtaka | |
| IL173337A0 (en) | Receptor | |
| EP1616880A4 (en) | LIGAND WITH AGONISTIC ACTIVITY AGAINST A MUTED RECEPTOR | |
| PT1558259E (pt) | Derivados de ureia como antagonistas do receptor de il-8 | |
| ZA200804010B (en) | Carbamate compounds as 5-HT4 receptor agonists | |
| GB0406039D0 (en) | Tungsten based catalyst system | |
| GB0321998D0 (en) | Receptor | |
| GB0307100D0 (en) | Receptor | |
| GB0329104D0 (en) | Receptor | |
| TJ20030779A (en) | Dibaferrol, having antimicrobe activity. | |
| ES1052119Y (es) | Maquina reactivadora de cortes de calzado. | |
| AU149317S (en) | Sanitary ware for pets | |
| GB0204278D0 (en) | Animal activity unit | |
| GB0303272D0 (en) | Animal activity unit |